Home > Articles > Retatrutide and liver fat: what the MASLD substudy measured
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Status: Investigational. Retatrutide is not approved by the FDA. The agency states it has "not been found safe and effective for any condition" and cannot be used in compounding under federal law [1]. See our approval status page for the full record.
Searches for "retatrutide liver fat" usually lead back to one paper. It is a 2024 Nature Medicine report of a randomized phase 2a study in metabolic dysfunction-associated steatotic liver disease (MASLD) [2]. This explainer covers how that study was built, what it measured, how the measurement works, and what the data cannot answer. It does not cover the drug's mechanism or side effects. Those topics have their own pages, and our retatrutide guide gives the trial-by-trial overview.
Where the liver data came from
The liver findings did not come from a standalone liver trial. They came from a group of participants inside a larger study, the phase 2 obesity trial published in the New England Journal of Medicine in 2023 [3]. That parent trial enrolled 338 adults with obesity, or with overweight plus a weight-related condition, and followed them for 48 weeks. It compared several retatrutide arms with placebo [3].
The Nature Medicine paper reports a subset of those participants who had excess liver fat at the start [2]. The design has three features worth noting:
It is human, randomized and placebo-controlled. Participants were assigned by chance to retatrutide or placebo, as in the parent trial [2][3].
It is small. The liver analysis included 98 of the parent trial's 338 participants, spread across several retatrutide arms and placebo, so each arm held relatively few people [2][3].
It is labelled phase 2a. That label marks early-stage evaluation. Studies at this stage are generally designed to see whether a signal exists and how large it might be, not to confirm effects for regulators.
How liver fat was measured: MRI-PDFF
The primary liver measurement was MRI proton density fat fraction (MRI-PDFF) [2]. This MRI technique estimates the share of liver tissue signal that comes from fat, reported as a percentage.
A few points help in reading the results:
It is non-invasive and quantitative. Unlike a biopsy, MRI-PDFF samples large areas of the liver and gives a number that can be repeated over time. That makes it common as an endpoint in early liver studies.
Thresholds matter. A liver fat fraction below about 5% is generally regarded in research as the normal range. The substudy enrolled people with a fat fraction of at least 10% [2].
It measures fat, not scarring or inflammation. MRI-PDFF does not directly assess steatohepatitis (inflammation) or fibrosis (scarring). Those are judged by biopsy histology or other markers, and they were not the primary endpoint here [2].
What the substudy reported
The main endpoint was the relative change in liver fat from baseline at 24 weeks. Liver fat was assessed again at 48 weeks [2].
The authors reported these results:
Liver fat fell across the retatrutide arms at 24 weeks. Mean relative reductions ranged from roughly 43% to roughly 82%, depending on the arm. Liver fat in the placebo arm changed very little [2].
Larger reductions appeared in the upper arms of the range studied. The pattern was graded across arms rather than all-or-nothing [2].
Many participants fell below the 5% threshold. In the upper arms, a large share of participants reached a liver fat fraction under 5% during follow-up [2].
Liver-fat change tracked other measurements. The authors described a close relationship between the drop in liver fat and changes in body weight, abdominal fat, and markers of insulin sensitivity and lipid metabolism [2].
These are reported measurements from a small, early-phase study. They are not a finding that retatrutide has any effect on liver disease outcomes.
What the substudy does not tell us
Several limits apply when reading the liver fat numbers:
Sample size. With 98 participants divided across several arms, the numbers per arm are small and estimates are imprecise. A few participants can shift an average.
Surrogate endpoint. Liver fat percentage is an imaging measurement. It is not the same as liver-related events such as cirrhosis or liver failure, and the study was not designed to assess those [2].
No histology endpoint. The primary readout was MRI-PDFF, so the substudy does not show whether steatohepatitis or fibrosis changed on biopsy [2].
Weight change is entangled. Liver fat moved closely with body weight [2]. The data cannot cleanly separate a weight-related effect from any liver-specific action of the glucagon component.
Population. Participants came from an obesity trial that excluded people with diabetes [3]. They are not necessarily representative of everyone with MASLD.
Duration. Forty-eight weeks says nothing about longer-term trajectories.
How it fits the wider research picture
The retatrutide liver data sit alongside a broader body of published research on incretin-based and multi-receptor compounds, in fatty liver disease and in obesity more generally:
GLP-1-based compounds and MASLD. A 2025 systematic review and meta-analysis in the Journal of Clinical Endocrinology & Metabolism examined GLP-1-based therapies in MASLD and metabolic dysfunction-associated steatohepatitis (MASH) [4].
Anti-obesity drugs and MASLD. A 2025 updated review in the World Journal of Gastroenterology covers the efficacy and safety of anti-obesity drugs in MASLD [5].
Triple agonism. A 2025 review in Current Cardiovascular Risk Reports covers triple-agonist approaches for obesity [6].
Retatrutide overview. A 2026 article in Expert Review of Clinical Pharmacology gives an overview of retatrutide in type 2 diabetes and obesity research [7].
Our own reading: phase 2a results of this size are generally regarded as early signals. Confirmation would require larger, longer trials with histology or clinical outcome endpoints. For the current status of phase 3 studies, see our retatrutide guide.
Frequently asked questions
Was the retatrutide liver study a separate trial?
No. It was a substudy of the phase 2 obesity trial, limited to participants with at least 10% liver fat at baseline on MRI-PDFF [2][3]. Its results, covering 98 participants, were published separately in Nature Medicine in 2024 [2].
Does a drop in MRI-PDFF mean liver disease improved?
Not necessarily. MRI-PDFF measures the fraction of fat in the liver, not inflammation or scarring [2]. Assessing liver-related clinical outcomes would require different endpoints and larger, longer trials.
Is retatrutide available for liver conditions?
No. Retatrutide is investigational, and the FDA states it has "not been found safe and effective for any condition" [1]. Our approval status page tracks the regulatory record.
Further reading
Papers like this one are easier to evaluate with a grounding in study design: surrogate endpoints, imaging biomarkers, subgroup analyses and what "phase 2a" really means. A good methods book makes those trade-offs explicit.
When comparing books on trial methods, these criteria are useful:
Accuracy and currency: a recent edition that covers modern endpoint and estimand terminology.
Coverage of surrogate endpoints: whether it explains why imaging or lab measures may not track outcomes.
Worked examples: real published trials analysed step by step, not only abstract formulas.
Statistical level: introductory, intermediate or technical, matched to the reader.
Format and price transparency: print, ebook or audio, with a clearly listed price and edition.
Bookshop.org lists titles through independent bookstores. That is useful for checking edition details and formats side by side before choosing.
We select reading-list categories independently of any commercial relationship. The About page explains how this site is funded and sourced.
Last updated: 19 October 2026.
Related on this site
Is retatrutide FDA approved? Legal status and approval timeline
Retatrutide: mechanism, trial findings and side effects explained
How to read retatrutide trial results: endpoints, placebo, dropouts
Books about clinical trials: a reading list for following research
Retatrutide vs tirzepatide: how the trial designs and data compare
Retatrutide mechanism of action: one molecule, three receptors
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.